Glenmark Pharmaceuticals is aiming to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year (FY24). The company is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology. The company will identify potential candidates for development purposes on a global scale as the drug maker moves up the value chain.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
